Waters Stock Price, News & Analysis

Waters Corporation reported a strong second quarter 2021 with sales reaching $682 million, a 31% increase from $520 million a year prior, driven by a 4% boost from foreign currency translation. GAAP diluted EPS rose to $2.69 from $1.98 in Q2 2020. For the first half of 2021, sales grew to $1,290 million, with 31% growth compared to the same period last year. The company anticipates full-year sales growth between 13% to 15% and expects non-GAAP EPS of $10.50 to $10.70.

Waters Corporation (NYSE:WAT) will host a live webcast for its Q2 2021 financial results on August 3, 2021, at 8:00 a.m. ET. Investors can access the call through Waters' official website. The replay will be available until August 10, 2021. Waters is a leader in specialty measurement, focusing on chromatography, mass spectrometry, and thermal analysis for life, materials, and food sciences. With over 7,400 employees and operations in 35 countries, Waters has a significant global presence.

Waters Corporation (NYSE:WAT) has launched the TRIOS AutoPilot software, enhancing its thermal analyzer product line under the TA Instruments Division. This software allows laboratory staff to develop standard operating procedures (SOPs) up to 25% faster and eliminates transcription errors, improving productivity and consistency in thermal analysis. It utilizes Google’s Blockly interface, making it user-friendly for script creation without advanced programming skills. The TRIOS AutoPilot includes built-in compliance features, ensuring regulatory adherence, and is available globally.

Waters Corporation (NYSE:WAT) has expanded its collaboration with Singapore's Bioprocessing Technology Institute (BTI) to enhance analytics in glycomics and metabolomics. The partnership aims to improve the rapid identification of complex biomolecules that are crucial for biologics manufacturing. Utilizing advanced instruments like the SYNAPT™ mass spectrometry system, the project addresses the challenges of characterizing biopharmaceuticals through data analytics and machine learning. This collaboration builds on a successful relationship since 2014, targeting cost reduction and efficiency in biomanufacturing processes.

Waters Corporation (NYSE: WAT) has appointed Wei Jiang to its Board of Directors, effective July 14, 2021. Wei currently serves as Executive Vice President at Bayer Pharmaceuticals for the China and APAC regions. His expertise in driving results in fast-growing markets, particularly in China, is viewed as a significant asset for Waters. Dr. Udit Batra, CEO, notes that Wei's experience aligns with the company's growth strategy in the pharmaceutical sector. Wei expressed enthusiasm about contributing to Waters' ongoing transformation, highlighting growth potential in China's pharma market.

Waters Corporation (NYSE:WAT) has launched the Waters Arc Premier System, the first liquid chromatography system designed for 2.5 – 3.5 micron columns featuring MaxPeak High Performance Surface (HPS) technology. This system reduces analyte-surface interactions, thereby improving analytical results for laboratories. Benefits include increased sensitivity, reproducibility, and potential savings of 2-3 days per assay by eliminating passivation. The combination of the Arc Premier System and MaxPeak Premier Columns aims to enhance productivity, accuracy, and confidence in pharmaceutical analysis.

Waters Corporation (NYSE:WAT) has launched the Waters™ SELECT SERIES™ MRT, an advanced mass spectrometer integrating Multi Reflecting Time-of-Flight (MRT) technology with enhanced DESI and new MALDI imaging sources. This device allows for rapid, precise identification of molecules, achieving speeds of up to 10Hz without losing mass accuracy. The SELECT SERIES MRT boasts a resolution of 200,000 FWHM, setting a new standard in mass spectrometry. Shipments are slated to begin in Q4 of this year, promising significant advancements in biological research and imaging applications.

Waters Corporation (NYSE:WAT) has launched a new RUO LC-MS test method, the SARS-CoV-2 LC-MS Kit, to enhance infectious disease research. This innovative method allows for the direct detection and quantification of SARS-CoV-2 Nucleocapsid (NCAP) peptides, yielding highly accurate results. Developed in collaboration with various research entities, this method aims to support high-throughput screening with reduced reliance on PCR reagents. The kit can quantify low levels of NCAP peptides, facilitating impactful studies on infection stages and future pandemic preparedness.